Please consider the existing drug is in a completely different format to what we are testing in iPPS which is injectable, the risk is definitely lower than a new drug but is far from fully mitigated. Repurposing helps reduce R&D costs and speeds up commercialization but doesn't mitigate all risks associated with FDA approval.
Positive results of Phase 3 will give us access to a huge market opportunity.
DYOR...
research reports and media, page-155
-
- There are more pages in this discussion • 4,274 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 23.0¢ | $85.35K | 365.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 280011 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 44703 | 3 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |